Get the Stockscreener App
2.67
4.98%
-0.14
Lixte Biotechnology Holdings Inc stock is traded at $2.67, with a volume of 19,551.
It is down -4.98% in the last 24 hours and down -11.59% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$2.81
Open:
$2.8493
24h Volume:
19,551
Relative Volume:
0.25
Market Cap:
$23.24M
Revenue:
-
Net Income/Loss:
$-4.08M
P/E Ratio:
-2.2706
EPS:
-1.1759
Net Cash Flow:
$-2.58M
1W Performance:
-8.25%
1M Performance:
-11.59%
6M Performance:
-41.58%
1Y Performance:
+122.50%
1-Day Range:
$2.65
$2.8493
1-Week Range:
$2.65
$2.9699
52-Week Range:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
433 PLAZA REAL, BOCA RATON
Compare LIXT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
2.67 | 24.46M | 0 | -4.08M | -2.58M | -1.1759 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
MACD Signal: How does Lixte Biotechnology Holdings Inc Equity Warrant perform in inflationary periodsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
LIXTW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary - Digital Journal
LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment - Digital Journal
Travel Stocks: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity WarrantInsider Buying & Expert Curated Trade Ideas - baoquankhu1.vn
Downgrade Watch: Will Lixte Biotechnology Holdings Inc stock go up in YEARJuly 2025 Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Should I Buy LIXT? LIXT 2026 AnalysisIntellectia AI™ - Intellectia AI
LIXTWLixte Biotechnology Hldgs Inc Latest Stock News & Market Updates - Stock Titan
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit - USA Today
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - USA Today
Should I invest in Lixte Biotechnology Holdings Inc. before earningsJuly 2025 Chart Watch & Expert Approved Trade Ideas - mfd.ru
Is Lixte Biotechnology Holdings Inc. stock a value trap2025 Stock Rankings & Accurate Entry and Exit Point Alerts - mfd.ru
Why Lixte Biotechnology Holdings Inc. stock could rally in 2025July 2025 WrapUp & Precise Swing Trade Alerts - mfd.ru
What is the next catalyst for Lixte Biotechnology Holdings Inc. Equity WarrantWeekly Loss Report & Verified Trade Idea Suggestions - mfd.ru
Will Lixte Biotechnology Holdings Inc. stock go up in YEARJuly 2025 Summary & Community Verified Trade Signals - mfd.ru
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary By Investing.com - Investing.com India
LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary - NewMediaWire
Lixte Elevates Liora Leadership to Advance Proton Therapy - TipRanks
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary - Investing.com
Lixte Biotechnology appoints Sidney Braun as CEO, Liora - TipRanks
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - ChartMill
Growth Review: Is Cognyte Software Ltd stock a smart retirement pickMarket Risk Summary & Real-Time Volume Surge Alerts - baoquankhu1.vn
How does Lixte Biotechnology Holdings Inc. Equity Warrant perform in inflationary periodsJuly 2025 Setups & Free Daily Entry Point Trade Alerts - mfd.ru
Why is Lixte Biotechnology Holdings Inc. stock going down2025 Pullback Review & Fast Entry Momentum Alerts - mfd.ru
LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy - Digital Journal
Can Lixte Biotechnology Holdings Inc. Equity Warrant be recession proofTrade Ideas & Short-Term High Return Strategies - mfd.ru
How is Lixte Biotechnology Holdings Inc. managing supply chain issuesWeekly Trade Recap & Capital Protection Trading Alerts - mfd.ru
How Lixte Biotechnology Holdings Inc. Equity Warrant stock trades during market volatilityJuly 2025 Levels & Daily Entry Point Trade Alerts - mfd.ru
How Lixte Biotechnology Holdings Inc. Equity Warrant stock compares to growth peersWeekly Profit Report & AI Driven Stock Price Forecasts - mfd.ru
LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment - NewMediaWire
LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment - Yahoo Finance
LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment - Digital Journal
Earnings Miss: Will Lixte Biotechnology Holdings Inc Equity Warrant stock benefit from M AMarket Activity Report & High Accuracy Investment Entry Signals - baoquankhu1.vn
Ideas Watch: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity WarrantTake Profit & Stepwise Trade Signal Implementation - baoquankhu1.vn
Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective - The Globe and Mail
Earnings Miss: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2025 Retail Activity & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
LIXTE Biotechnology Targets Cancer Treatment Resistance with PP2A Inhibitor Platform - citybuzz -
Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective - NewMediaWire
Market Overview: What makes Lixte Biotechnology Holdings Inc. Equity Warrant stock attractive todayJuly 2025 Breakouts & Safe Capital Growth Plans - baoquankhu1.vn
De La Soul To Lead ‘Good Health’ Summit at Morehouse College - Okayplayer
LIXTE Biotechnology regains Nasdaq compliance - MSN
Is Lixte Biotechnology Holdings, Inc. overvalued or undervalued? - Markets Mojo
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):